Method of treating graft versus host disease using adipose derived mesenchymal stem cells
The present invention relates to the use of a particular type of adipose tissue derived mesenchymal stem cells (AD-MSCs), which exert immunosuppressive properties, in the manufacture of a pharmaceutical composition for the prevention and treatment of the graft-versus-host disease (GVHD) produced after allogeneic hematopoietic stem cell transplantation.
1. A method of reducing severity or treating graft-versus-host disease (GVHD) in a mammal given a bone marrow transplant (BMT), the method comprising administering a pharmaceutical composition to the mammal given the BMT, wherein the pharmaceutical composition comprises:
i) a therapeutically or prophylactically effective amount of an adipose derived mesenchymal stem cell (AD-MSC) population that is:
(a) negative for CD3, CD11 b, CD14, CD19, CD31, CD34, CD45, CD62L, CD95L, CD117, and HLA-DR cell surface markers, and
(b) positive for CD13, CD29, CD44, CD49e, CD73, CD90, CD105, CD166, and HLA-ABC cell surface markers, and
ii) a pharmaceutically acceptable vehicle.
2. The method of claim 1 , wherein said pharmaceutical composition is administered in combination with an additional pharmaceutical composition for the treatment of graft-versus-host disease.
3. The method of claim 2 , wherein said additional pharmaceutical composition is administrated simultaneously or sequentially to the pharmaceutical composition comprising an adipose tissue derived cell population.
4. The method according to claim 1 , wherein said graft-versus-host disease is selected from the group consisting of chronic graft-versus-host disease and acute graft-versus-host disease.
5. The method according to claim 1 , wherein said pharmaceutical composition is a pharmaceutical composition for parenteral administration.
6. The method according to claim 1 , wherein said cell population is from human origin.
7. The method according to claim 1 , wherein the mammal is human.